secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001818331-23-000006
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeneDx (formerly Sema4) eyes 37-40% revenue growth to ~$170-173M in 2022; guides 2023 rev $205-220M
--------------------------------------------------------------------------------

- Preliminary pro forma 2022 revenue $170-173M, up 37-40% YoY from $123.7M.
- Pro forma test result volume >180,000 (+23% YoY); adjusted gross margin 38-41% (up from 34%).
- 2023 guidance: revenue $205-220M; cash burn for continuing ops $95-110M; targeting profitability in 2025.
- Name changed to GeneDx Holdings Corp.; common stock begins trading under WGS on Jan 10, 2023.
- CEO highlights combination of GeneDx and Centrellis platforms to accelerate precision medicine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833123000006/0001818331-23-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833123000006/smfr-20230109.htm
  HTML page:      https://secwatch.observer/filing/0001818331-23-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer